Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 4/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 9/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344080 | 0.85 | MET (0.52) | DYRK1AMETACLYHTR6HTR2C | |
| SCHEMBL1743494 | 0.83 | MET (0.51) | DYRK1AMETACLYHTR6HTR2C | |
| SCHEMBL14468673 | 0.81 | DYRK1A (0.50) | DYRK1AMETACLYHTR6HTR2C | |
| SCHEMBL3868823 | 0.80 | TDP1 (0.44) | DYRK1AMETACLYHTR6CCKBR | |
| Phenol SCHEMBL5484795 | 0.77 | MET (0.52) | DYRK1AMETACLYHTR6HTR2C | |
| SCHEMBL3874477 | 0.76 | SMN1; SMN2 (0.36) | DYRK1AMETACLYCYP1A2ALDH1A1 | |
| SCHEMBL1339567 | 0.72 | DYRK1A (0.56) | DYRK1AACLYCYP1A2ALDH1A1HPGD | |
| SCHEMBL3762990 | 0.71 | ALDH1A1 (0.56) | DYRK1ACYP1A2ALDH1A1HPGDTSHR | |
| SCHEMBL20007689 | 0.71 | HTR7 (0.46) | DYRK1AMETACLYHTR6HTR2C | |
| SCHEMBL14280359 | 0.70 | HTR6 (0.48) | METHTR6HTR2CHTR7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | claimed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | claimed |
| EP-2297166-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-03-23 | — | — | EP | claimed |
| US-20100076036-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| WO-2010012806-A2 | SUBSTITUTED INDOLE SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-04 | — | — | WO | claimed |
| EP-2149573-A1 | Substituted indole sulfonamide compounds their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | claimed |
| EP-2114929-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-03-22 | — | — | US | claimed |
| WO-2007028460-A1 | TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-03-15 | — | — | WO | claimed |
| EP-1747779-A1 | Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | claimed |
| EP-1718609-A1 | SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-11-08 | — | — | EP | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| WO-2005077897-A1 | SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | claimed |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | US | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076036-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | HTR6, HTR2A, HTR2C | DYRK1A 1941/4885MET 3237/4885ACLY 3613/4885 |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | DYRK1A 692/4885MET 605/4885ACLY 3859/4885 |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | DYRK1A 2606/4885MET 2334/4885ACLY 4569/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | DYRK1A 3026/4885MET 1392/4885ACLY 4043/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | DYRK1A 2606/4885MET 2334/4885ACLY 4569/4885 |
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | DYRK1A 3108/4885MET 3429/4885ACLY 4182/4885 |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | DYRK1A 3108/4885MET 3429/4885ACLY 4182/4885 |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | DYRK1A 1829/4885MET 952/4885ACLY 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.